SUTRO BIOPHARMA INC (STRO) Fundamental Analysis & Valuation

NASDAQ:STRO • US8693672011

Current stock price

38.6 USD
+3.21 (+9.07%)
Last:

This STRO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. STRO Profitability Analysis

1.1 Basic Checks

  • STRO had negative earnings in the past year.
  • STRO had a negative operating cash flow in the past year.
  • STRO had negative earnings in each of the past 5 years.
  • STRO had negative operating cash flow in 4 of the past 5 years.
STRO Yearly Net Income VS EBIT VS OCF VS FCFSTRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M

1.2 Ratios

  • STRO's Return On Assets of -109.93% is on the low side compared to the rest of the industry. STRO is outperformed by 78.64% of its industry peers.
Industry RankSector Rank
ROA -109.93%
ROE N/A
ROIC N/A
ROA(3y)-63.79%
ROA(5y)-50.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
STRO Yearly ROA, ROE, ROICSTRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for STRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
STRO Yearly Profit, Operating, Gross MarginsSTRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. STRO Health Analysis

2.1 Basic Checks

  • STRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • STRO has more shares outstanding than it did 1 year ago.
  • STRO has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for STRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
STRO Yearly Shares OutstandingSTRO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M
STRO Yearly Total Debt VS Total AssetsSTRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • STRO has an Altman-Z score of -7.61. This is a bad value and indicates that STRO is not financially healthy and even has some risk of bankruptcy.
  • STRO has a Altman-Z score of -7.61. This is in the lower half of the industry: STRO underperforms 70.10% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.61
ROIC/WACCN/A
WACC9.51%
STRO Yearly LT Debt VS Equity VS FCFSTRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 2.01 indicates that STRO has no problem at all paying its short term obligations.
  • STRO has a worse Current ratio (2.01) than 78.06% of its industry peers.
  • A Quick Ratio of 2.01 indicates that STRO has no problem at all paying its short term obligations.
  • STRO's Quick ratio of 2.01 is on the low side compared to the rest of the industry. STRO is outperformed by 76.50% of its industry peers.
Industry RankSector Rank
Current Ratio 2.01
Quick Ratio 2.01
STRO Yearly Current Assets VS Current LiabilitesSTRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. STRO Growth Analysis

3.1 Past

  • STRO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.53%, which is quite impressive.
  • The Revenue has grown by 65.18% in the past year. This is a very strong growth!
  • STRO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.13% yearly.
EPS 1Y (TTM)25.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.56%
Revenue 1Y (TTM)65.18%
Revenue growth 3Y14.78%
Revenue growth 5Y19.13%
Sales Q2Q%-21.35%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.97% on average over the next years. This is quite good.
  • STRO is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -7.03% yearly.
EPS Next Y61.91%
EPS Next 2Y26.56%
EPS Next 3Y11.55%
EPS Next 5Y13.97%
Revenue Next Year-65.33%
Revenue Next 2Y-43.52%
Revenue Next 3Y-35.8%
Revenue Next 5Y-7.03%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
STRO Yearly Revenue VS EstimatesSTRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M
STRO Yearly EPS VS EstimatesSTRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. STRO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for STRO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
STRO Price Earnings VS Forward Price EarningsSTRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
STRO Per share dataSTRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.56%
EPS Next 3Y11.55%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. STRO Dividend Analysis

5.1 Amount

  • No dividends for STRO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

STRO Fundamentals: All Metrics, Ratios and Statistics

SUTRO BIOPHARMA INC

NASDAQ:STRO (4/30/2026, 1:56:43 PM)

38.6

+3.21 (+9.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.66
Industry Growth13.04
Earnings (Last)03-23
Earnings (Next)05-06
Inst Owners39.98%
Inst Owner Change0%
Ins Owners0.51%
Ins Owner Change0.29%
Market Cap639.60M
Revenue(TTM)102.48M
Net Income(TTM)-191.09M
Analysts78.75
Price Target30.6 (-20.73%)
Short Float %4.64%
Short Ratio3.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-38.94%
Min EPS beat(2)-58.49%
Max EPS beat(2)-19.39%
EPS beat(4)1
Avg EPS beat(4)-9.53%
Min EPS beat(4)-58.49%
Max EPS beat(4)65.88%
EPS beat(8)3
Avg EPS beat(8)0.52%
EPS beat(12)5
Avg EPS beat(12)14.15%
EPS beat(16)6
Avg EPS beat(16)11.74%
Revenue beat(2)2
Avg Revenue beat(2)20.48%
Min Revenue beat(2)4.07%
Max Revenue beat(2)36.89%
Revenue beat(4)4
Avg Revenue beat(4)106.59%
Min Revenue beat(4)4.07%
Max Revenue beat(4)338.47%
Revenue beat(8)7
Avg Revenue beat(8)52.93%
Revenue beat(12)10
Avg Revenue beat(12)107.33%
Revenue beat(16)12
Avg Revenue beat(16)85.08%
PT rev (1m)-7.69%
PT rev (3m)-11.39%
EPS NQ rev (1m)58.86%
EPS NQ rev (3m)60.86%
EPS NY rev (1m)56.69%
EPS NY rev (3m)55.94%
Revenue NQ rev (1m)-23.97%
Revenue NQ rev (3m)-23.97%
Revenue NY rev (1m)-22.21%
Revenue NY rev (3m)-22.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.49
EYN/A
EPS(NY)-8.57
Fwd EYN/A
FCF(TTM)-10.8
FCFYN/A
OCF(TTM)-10.7
OCFYN/A
SpS6.18
BVpS-7.99
TBVpS-7.99
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -109.93%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.79%
ROA(5y)-50.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 23.14%
Cap/Sales 1.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.01
Quick Ratio 2.01
Altman-Z -7.61
F-Score4
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)43.12%
Cap/Depr(5y)116.81%
Cap/Sales(3y)3.15%
Cap/Sales(5y)9.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.53%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.56%
EPS Next Y61.91%
EPS Next 2Y26.56%
EPS Next 3Y11.55%
EPS Next 5Y13.97%
Revenue 1Y (TTM)65.18%
Revenue growth 3Y14.78%
Revenue growth 5Y19.13%
Sales Q2Q%-21.35%
Revenue Next Year-65.33%
Revenue Next 2Y-43.52%
Revenue Next 3Y-35.8%
Revenue Next 5Y-7.03%
EBIT growth 1Y56.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year19.25%
EBIT Next 3Y2.49%
EBIT Next 5YN/A
FCF growth 1Y8.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.47%
OCF growth 3YN/A
OCF growth 5YN/A

SUTRO BIOPHARMA INC / STRO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SUTRO BIOPHARMA INC (STRO) stock?

ChartMill assigns a fundamental rating of 1 / 10 to STRO.


Can you provide the valuation status for SUTRO BIOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to SUTRO BIOPHARMA INC (STRO). This can be considered as Overvalued.


What is the profitability of STRO stock?

SUTRO BIOPHARMA INC (STRO) has a profitability rating of 0 / 10.


What is the financial health of SUTRO BIOPHARMA INC (STRO) stock?

The financial health rating of SUTRO BIOPHARMA INC (STRO) is 2 / 10.